Organigram Global Inc.

Business Wire•7/20/2026

Organigram Provides Business Update Highlighting Initial Sanity Performance and Canadian Market Share

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), today provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement. "The first quarter following the acquisition of Sanity marks an important milest.

Seeking Alpha•5/20/2026

Organigram: Record Harvests Are The Root Of Market Share Erosion

Seeking Alpha•5/12/2026

Organigram Global Inc. (OGI:CA) Q2 2026 Earnings Call Transcript

Organigram Says Vape Weakness Pressures Margins

Organigram Global Inc. (NASDAQ:OGI) reported weaker second-quarter fiscal 2026 results as declining vape and infused pre-roll sales weighed on revenue and profitability.

Zacks Investment Research•5/12/2026

OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

OrganiGram (OGI) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.

Organigram Global Q2 Earnings Call Highlights

Organigram Global NASDAQ: OGI reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market growth and continued challenges with international flower specifications.

Business Wire•5/12/2026

Organigram Reports Second Quarter Fiscal 2026 Results

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year).

Business Wire•5/6/2026

Organigram to Report Second Quarter Fiscal 2026 Results on May 12th, 2026

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use t.